Hiroshi Bando1,2* 1Medical Research/Tokushima University, Tokushima, Japan 2Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Kyoto, Japan
Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan. Received date: 06 January 2021; Accepted date: 10 February 2021; Published date: 17 February 2021
Citation: Bando H. Direction for Basal Insulin Therapy by Once Daily Injection in the Clinical Practice. Diab Res Open Access. 2021 Feb 17;3(1):11-15.
Keywords: American Diabetes Association (ADA), Dual Action of Liraglutide and Insulin Degludec (DUAL) studies, Xultophy, Multiple Daily Injection (MDI), Once Daily Injection
American Diabetes Association (ADA) has announced the new version of the standards of Medical Care in Diabetes-2021. The guideline of the diabetic patients with Older Adults seems to be used for a wide range of clinical practice. Among them, several impressive comments were found, where “Once-daily basal insulin injection therapy is associated with minimal side effects and maybe a reasonable option in many elder patients”. Recent topic includes Dual Action of Liraglutide and insulin degludec (DUAL) studies, and Xultophy has shown beneficial efficacy. Consequently, the trend would be developed from multiple daily injection (MDI) method to once daily injection.